[go: up one dir, main page]

WO2017184871A9 - Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation - Google Patents

Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation Download PDF

Info

Publication number
WO2017184871A9
WO2017184871A9 PCT/US2017/028646 US2017028646W WO2017184871A9 WO 2017184871 A9 WO2017184871 A9 WO 2017184871A9 US 2017028646 W US2017028646 W US 2017028646W WO 2017184871 A9 WO2017184871 A9 WO 2017184871A9
Authority
WO
WIPO (PCT)
Prior art keywords
carbidopa
methods
prodrug
dopa
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/028646
Other languages
English (en)
Other versions
WO2017184871A1 (fr
Inventor
Philip R. Kym
Eric Voight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority to EP17721269.3A priority Critical patent/EP3445346A1/fr
Priority to JP2018554585A priority patent/JP2019515908A/ja
Priority to US16/164,073 priority patent/US20190224220A1/en
Priority to EP23192663.5A priority patent/EP4295909A3/fr
Publication of WO2017184871A1 publication Critical patent/WO2017184871A1/fr
Publication of WO2017184871A9 publication Critical patent/WO2017184871A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne (a) des promédicaments de carbidopa, (b) des combinaisons et des compositions pharmaceutiques comprenant un promédicament de carbidopa et/ou un promédicament de L-dopa, et (c) des méthodes de traitement de la maladie de Parkinson et d'autres affections associées comprenant l'administration d'un promédicament de carbidopa et d'un promédicament de L-dopa à un sujet atteint de la maladie de Parkinson.
PCT/US2017/028646 2016-04-20 2017-04-20 Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation Ceased WO2017184871A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP17721269.3A EP3445346A1 (fr) 2016-04-20 2017-04-20 Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation
JP2018554585A JP2019515908A (ja) 2016-04-20 2017-04-20 カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
US16/164,073 US20190224220A1 (en) 2016-04-20 2017-04-20 Carbidopa and L-Dopa Prodrugs and Methods of Use
EP23192663.5A EP4295909A3 (fr) 2016-04-20 2017-04-20 Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325200P 2016-04-20 2016-04-20
US62/325,200 2016-04-20

Publications (2)

Publication Number Publication Date
WO2017184871A1 WO2017184871A1 (fr) 2017-10-26
WO2017184871A9 true WO2017184871A9 (fr) 2018-01-25

Family

ID=58668985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/028646 Ceased WO2017184871A1 (fr) 2016-04-20 2017-04-20 Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation

Country Status (4)

Country Link
US (1) US20190224220A1 (fr)
EP (2) EP3445346A1 (fr)
JP (4) JP2019515908A (fr)
WO (1) WO2017184871A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6567049B2 (ja) 2014-10-21 2019-08-28 アッヴィ・インコーポレイテッド カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
WO2019097120A1 (fr) 2017-11-16 2019-05-23 Orion Corporation Nouvelle utilisation et nouvelles formes posologiques pharmaceutiques
TWI816716B (zh) 2017-11-24 2023-10-01 丹麥商Ｈ 朗德貝克公司 用於治療帕金森病之新兒茶酚胺前驅藥
CA3117983A1 (fr) 2018-11-15 2020-05-22 Abbvie Inc. Formulations pharmaceutiques pour une administration sous-cutanee
WO2020115753A1 (fr) * 2018-12-05 2020-06-11 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Inhibiteurs de l-dopa et/ou dopa-décarboxylase conjugués au sucre pour le traitement de troubles sensibles à la dopamine
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN113727712B (zh) 2019-05-21 2024-11-15 H.隆德贝克有限公司 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药
US12319710B2 (en) 2019-05-21 2025-06-03 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's diseases
EP3972959A1 (fr) 2019-05-21 2022-03-30 H. Lundbeck A/S Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
US12384765B2 (en) 2019-05-21 2025-08-12 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's Disease
JP2024010252A (ja) 2021-03-10 2024-01-24 田辺三菱製薬株式会社 パーキンソン病治療のための組合せ医薬
WO2024104331A1 (fr) * 2022-11-14 2024-05-23 江苏恒瑞医药股份有限公司 Promédicament de lévodopa

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2070994T3 (es) * 1989-04-20 1995-06-16 Zambon Spa Profarmaco de dopamina.
GB9102812D0 (en) * 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) * 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
CA2490626A1 (fr) * 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. Promedicament, utilisation de ce dernier en medecine et procede de production de ce promedicament
US7101912B2 (en) * 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
MXPA06002344A (es) * 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
WO2005041926A1 (fr) * 2003-10-31 2005-05-12 Alza Corporation Compositions et formes posologiques pour une absorption amelioree d'acide 3-amino-n-butyl-phosphinique
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
NZ590128A (en) * 2004-07-06 2012-08-31 Abbott Lab Prodrugs of HIV protease inhibitors
US7709527B2 (en) * 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
MX2010012648A (es) * 2008-05-20 2010-12-14 Neurogesx Inc Analogos de acetaminofeno solubles en agua.
JP5902705B2 (ja) * 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
JP6567049B2 (ja) * 2014-10-21 2019-08-28 アッヴィ・インコーポレイテッド カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法

Also Published As

Publication number Publication date
EP4295909A2 (fr) 2023-12-27
JP2024020212A (ja) 2024-02-14
US20190224220A1 (en) 2019-07-25
JP2019515908A (ja) 2019-06-13
EP3445346A1 (fr) 2019-02-27
WO2017184871A1 (fr) 2017-10-26
JP2022000428A (ja) 2022-01-04
JP2025163273A (ja) 2025-10-28
EP4295909A3 (fr) 2024-07-17

Similar Documents

Publication Publication Date Title
WO2017184871A9 (fr) Promédicaments de carbidopa et de l-dopa et méthodes d'utilisation
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
HK1243922A1 (zh) 用於治疗帕金森病的aadc多核苷酸
PH12018501072A1 (en) Modified release orally administered amino acid formulations
EP4299128A3 (fr) Compositions d'inhibiteurs de dopa-décarboxylase
AU2015352158A8 (en) Medicaments for slowing Parkinson's Disease
EP4574832A3 (fr) Promédicaments de dantrolène et leurs procédés d'utilisation
WO2015159155A3 (fr) Nouvelles formulations d'adémétionine
EP4560024A3 (fr) Analogues deutérés de d-sérine et leurs utilisations
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
WO2016057658A8 (fr) Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
MX2019000849A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
WO2016057660A8 (fr) Agonistes, composés, compositions pharmaceutiques ppar et méthodes d'utilisation de ceux-ci
HK1245638A1 (en) Levodopa and carbidopa intestinal gel and methods of use
HK40037165A (en) New catecholamine prodrugs for use in the treatment of parkinson's disease
HK40027110A (en) Aadc polynucleotides for the treatment of parkinson's disease
HK1252359A1 (zh) 用於治疗疼痛的曲唑酮和加巴喷丁的组合
IN2013MU02575A (fr)

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018554585

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2017721269

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17721269

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017721269

Country of ref document: EP

Effective date: 20181120